Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Mar 26, 2009

Premium

Title: siRNA Targeting KRAS

Number: 7,507,811

Filed: Dec. 4, 2006

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes."


Title: RNAi Modulation of RSV and Therapeutic Uses Thereof

Number: 7,507,809

Filed: Jan. 6, 2006

Inventor: Rachel Meyers, Alnylam Pharmaceuticals

The invention, the patent's abstract states, is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of [RNAi] agents, as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the … invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels, and viral titers in a subject, e.g., a mammal, such as a human. These findings can be applied to other respiratory viruses," the abstract adds.


Title: Lipoplex Formulations for Specific Delivery to Vascular Endothelium

Number: 20090074852

Filed: April 20, 2007 PCT Filed: April 20, 2007

Lead Inventor: Jorg Kaufmann, Silence Therapeutics

The invention, the patent application's abstract states, "is related to a lipid composition contained in and/or containing a carrier comprising at least a … lipid component, at least a … helper lipid, and a shielding compound [that] is optionally removable from the lipid composition under in vivo conditions."

The lipid composition-containing carrier, the abstract notes, has an osmolarity of about 50 to 600 mosmol per kilogram, while the liposomes formed by the lipid component, the helper lipid, and the shielding compound in the carrier have a particle size of about 20 to 200 nanometers.


Title: Methods of Inhibiting Tumor Cell Proliferation with FoxM1 siRNA

Number: 20090075376

Filed: Jan. 6, 2005 PCT Filed: Jan. 6, 2005

Lead Inventor: Robert Costa, University of Illinois

The invention, the patent application's abstract states, comprises "methods for inhibiting tumor cell proliferation by inhibiting Fox M1B — also called Fox M1 — activity in a tumor cell. The invention also provides FoxM1B siRNA molecules and pharmaceutical compositions comprising FoxM1B siRNA molecules [that] … can inhibit FoxM1B activity and can inhibit proliferation of tumor cells. The invention further provides methods for preventing tumor growth, progression, or both in an animal comprising inhibiting FoxM1B activity using siRNA molecules or pharmaceutical compositions comprising FoxM1B siRNA molecules."


Title: Gene Silencing by Systemic RNA Interference

Number: 20090077679

Filed: Feb. 22, 2008

Lead Inventor: Craig Hunter, Harvard University

The invention, the patent application's abstract states, comprises "nucleic acid and protein sequences relating to a gene required for systemic RNAi.

"The SID-1 protein is shown to be required for systemic RNAi," and the application claims "nucleic acids, vectors, transformed cells, transgenic animals, polypeptides, and antibodies relating to the sid-1 gene and protein," according to the abstract. "Also provided are methods for reducing the expression of a target gene in a cell, a population of cells, or an animal."

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.